Polatuzumab Clinical Trials

3 actively recruiting trials across 2 locations

▼ -1 trial since June 2026

Also known as: Polatuzumab Vedotin, Polatuzumab vedotin, DCDS4501S, RG7596, Polivy, RO5541077

Pipeline

Phase 2: 3

Top Sponsors

Memorial Sloan Kettering Cancer Center1
Lazaros Lekakis1
Jennifer Crombie, MD1

Indications

Cancer3
Aggressive Non-Hodgkin Lymphoma1
Lymphoma, Large B-Cell, Diffuse1
High-grade B-cell Lymphoma1
Refractory Non-Hodgkin Lymphoma1

Miami, Florida2 trials

A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma

University of Miami Sylvester Cancer Center

Phase 2

CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL).

University of Miami

Phase 2

Basking Ridge, New Jersey1 trial

A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.